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In vitro and in vivo activity of a new small-molecule
inhibitor of HDAC6 in mantle cell lymphoma
Cancer origin and development is associated not only
with genetic alterations, but also with the disturbance of
epigenetic profiles.1 In this regard, the tumoral epigenome
is characterized by both specific and general shifts in the
DNA methylation and histone-modification landscapes.1
However, in contrast to genetic disruption, the effect of
epigenetic modifications or marks may potentially be
reversed by the use of drugs that target enzymes involved
in adding, removing or signaling DNA methylation and
histone modifications.1 This basic knowledge has been
adopted into clinical practice, and inhibitors of histone
deacetylases and DNA demethylating agents have been
approved for use in the therapy of hematologic malignan-
cies, such as cutaneous T-cell lymphoma and myelodys-
plastic syndrome, respectively.2 Other promising epige-
netic drugs include inhibitors of histone methyltrans-
ferases,2 histone demethylases,2 histone kinases,3 and
bromodomain proteins that interfere with the ‘reading’
of acetylated histone residues.4,5
Histone deacetylase 6 (HDAC6) is a protein modifier
that is an increasingly attractive pharmacological target.
It is a member of class IIb of the histone deacetylase fam-
ily, together with HDAC10.6 Unlike most HDACs,
HDAC6 is expressed primarily in the cytoplasm and its
deacetylase activity involves mainly non-histone sub-
strates, such as the cytoskeletal protein α-tubulin and the
heatshock protein Hsp90. In this way, it plays an impor-
tant role in microtubule dynamics and chaperone signal-
ing.6 HDAC6 is involved in various human diseases, and
in cancer promotes tumor initiation, development, and
metastasis, having been shown to be over-expressed in
various tumor types. Interestingly, the observation that
the HDAC6 knock-out mouse is not lethal7 in contrast to
those undergoing complete loss of class I, II and III
HDACs, suggests that specific HDAC6 inhibitors may be
better tolerated than pan-HDAC inhibitors or drugs that
target the other HDAC classes. In this regard, the com-
pounds tubacin, its derivative tubastatin A and ACY-
1215 (Ricolinostat) are selective HDAC6 inhibitors.8 The
latter agent is undergoing clinical trials as a single agent
or in combination for the treatment of multiple myeloma
and other tumors (clinicaltrials.gov identifiers: 01997840,
01323751, 02189343, 01583283). Given the interest in
HDAC6 inhibition, we decided to design, synthesize, and
test the activity of new small-molecule inhibitors of
HDAC6 that could have a potential antitumor impact.
Almost all HDAC inhibitors, including those of
HDAC6, share a typical structure comprising three pri-
mary regions: i) a zinc-chelating group that binds the zinc
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Figure 1. Chemical structure and HDAC specificity of QTX125 and its effect on α-tubulin acetylation and cell growth. (A) (Top) Chemical structure of QTX125.
(Below) In vitro enzymatic activity of 11 HDACs upon QTX125 use. (B) Growth-inhibitory effect of QTX125 in cancer cell lines determined by the MTS assay. (C)
(Left) Western-blot assays in MINO, REC-1, IRM-2 and HBL-2 cells show the induction of α-tubulin hyperacetylation upon QTX125 administration. Sodium
butyrate is shown as an HDAC inhibitor that does not affect HDAC6 (negative control). TSA is shown as an HDAC inhibitor that affects all HDAC classes, including
HDAC6 (positive control). The effect of the three available specific HDAC6 inhibitors (tubastatin A, tubacin, and ACY1215) is also shown. Total α-tubulin is used
as a loading control. (Right) Growth-inhibitory effect of QTX125 in the mantle cell lymphoma  cell lines determined by the MTS assay in comparison to the other,
previously described HDAC6 inhibitors. CML: chronic myelogenous leukemia.
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ion present at the active site, preventing activation of the
enzyme (typically, a hydroxamic acid in HDAC6
inhibitors); ii) a hydrophobic linker region that mimics
the 1,4-butylene alkyl chain of the lysine residue present
in the natural substrates of HDACs; and iii) a filling-cap
group, usually an aromatic or heteroaromatic ring, that
binds to the substrate-binding region of the enzyme and
fills the entrance to the hydrophobic channel. Variations
in one or more of these regions may result in greater
selectivity to one isoform than the others. Thus, the
HDAC6 hydrophobic channel appears wider than that of
other HDAC subtypes, suggesting that replacement of
the traditional alkyl chain linker with bulkier and shorter
aromatic moieties might enhance HDAC6 selectivity.
Taking into account these HDAC6 inhibitor structures,
the structural differences between HDAC6 and other
HDAC isoforms (and also the structural information of
our previously developed HDAC inhibitors9), a new
potential HDAC6 selective inhibitor was designed and
synthesized: QTX125 [3-(3-furyl)-N-{4-
[(hydroxyamino)carbonyl]benzyl}-5-(4-hydroxyphenyl)-
1H-pyrrole-2-carboxamide] (Figure 1A). QTX125 was
synthesized by means of a 7-step synthetic procedure,
starting with an aldol condensation reaction of 4-hydrox-
yacetophenone with 3-furaldehyde to obtain the corre-
sponding α,β-unsaturated ketone. This ketone was then
treated with ethyl nitroacetate and triethylamine, the
mixture obtained being oxidized by means of the Nef
reaction with sodium ethoxide to yield the corresponding
γ-ketoester. Through a cyclization reaction of this ester in
the presence of ammonium salts,10 good yields of the
ethyl 3-(furan-3-yl)-5-(4-hydroxyphenyl)-1H-pyrrole-2-
carboxylate were obtained. Deprotection of the methyl
ester group of the pyrrole, and coupling with the methyl
4-(aminomethyl)benzoate yielded the corresponding
amide. Further elaboration produced the final hydroxam-
ic acid. It is noteworthy that, as designed, the synthesis is
well-suited to kilogram-scale production. 
The selectivity of QTX125 for inhibiting HDAC6 func-
tion in comparison with all the other HDACs was meas-
ured by determining the in vitro enzymatic activity of 
50 mM of each acetylated AMC-labeled peptide substrate
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Figure 2. QTX125 use in mantle cell lymphoma (MCL) induces cell death by apoptosis and inhibits lymphoma growth in xenografted mice. (A) Quantification
of the flow cytometry values of annexin V/PI incorporation (Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit, Invitrogen) to show the proapoptotic effect of
QTX125 on the MCL cell lines MINO, REC-1, IRM-2 and HBL-2. (B) Induction of programmed cell death upon QTX125 administration shown by the cleavage of
caspase-9, caspase-8, caspase-3, and PARP in the western blot assay. Actin is used as a loading control. (C) Antitumoral activity of QTX125 in REC-1 and MINO
xenografts in nude mice. For REC-1, tumor volume was monitored over time in vehicle and QTX125-treated (two regimens) and cyclophosphamide-treated mice
(Mann–Whitney U-test). qdx5: daily dosing for 5 days; 5/2x4w: 5 days of dosing/2 days off for 4 weeks; qdx28: daily dosing for 28 days. For MINO, tumor volume
was monitored over time in vehicle and and QTX125-treated mice (5/2x4w: 5 days of dosing/2 days off for 4 weeks). The vehicle group arm was stopped at 15
days for ethical reasons. 
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and an optimal concentration of the corresponding
enzyme (HDAC1, HDAC2, HDAC3, HDAC4, HDAC5,
HDAC6, HDAC7, HDAC8, HDAC9, HDAC10 and
HDAC11) (Online Supplementary Appendix). QTX125
demonstrated an exceptional specificity for inhibiting
HDAC6 enzymatic activity (Figure 1A). To test the capac-
ity of QTX125 as an antitumor agent, we first deter-
mined the 72-hour IC50 values using the MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] assay in a panel of 48
human cancer cell lines, including solid tumors (breast,
prostate, kidney, colorectal, lung, pancreas, liver,
osteosarcoma, glioblastoma, fibrosarcoma, melanoma,
and ovarian cancer), and hematologic malignancies
[chronic myelogenous leukemia, multiple myeloma,
Hodgkin lymphoma, Burkitt cell lymphoma, follicular
lymphoma, and mantle cell lymphoma (MCL)] (Online
Supplementary Appendix). We observed that QTX125 had
the strongest growth-inhibitory effect in Burkitt cell lym-
phoma, follicular lymphoma, and MCL (Figure 1B). 
Mantle cell lymphoma therapy constitutes an unmet
medical need because there is no single accepted treat-
ment approach for the disease.11 R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone)
is a common first-line therapeutic approach, but is of lim-
ited duration.12 Due to the antitumoral effect of QTX125
in MCL cell lines and its specificity in blocking HDAC6
activity that we observed here, we decided to character-
ize in detail QTX125 in MCL, further encouraged by the
finding that HDAC6 activity is essential for MCL
growth.13 The growth-inhibitory effect of QTX125 at
nanomolar levels in the aforementioned MCL cell lines
was confirmed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, and the cell
count of alive cells by trypan blue staining and by flow
cytometry of AnnexinV/PI (Online Supplementary Figure
S1). A further analysis of the MCL cell lines MINO, REC-
1, IRM-2 and HBL-2 also showed that the use of QTX125
induced dose-dependent hyperacetylation of α-tubulin
(Figure 1C), the best known target of HDAC6, thus pro-
viding further validation that the drug targets this partic-
ular enzyme. Trichostatin A was used as a general
inhibitor for HDAC classes I, IIa, IIB (including HDAC6)
and IV, whereas sodium butyrate was used as an HDAC
inhibitor that does not affect HDAC6 (Figure 1C).14 The
three available HDAC6 inhibitors (tubastatin A, tubacin,
and ACY1215) were also used as specific positive con-
trols for HDAC6-inhibition-mediated hyperacetylation of
α-tubulin (Figure 1C). Importantly, QTX125 was able to
induce α-tubulin acetylation even at 10 nM concentra-
tion, whereas the other HDAC6 inhibitors did not (Figure
1C). In our MCL cell lines, and with QTX125, we did not
observe any increase in CD20 expression as occurs with
other HDAC6 inhibitors in Burkitt and diffuse large B-cell
lymphoma cell lines15 (Online Supplementary Figure S2).
Strikingly, QTX125 was the most powerful inhibitor of
growth in the MCL cell lines compared with the other
three HDAC6 inhibitors reported  (Figure 1C).
We also showed that the observed inhibition of cell
proliferation upon QTX125 administration was associat-
ed with the induction of subsequent apoptosis demon-
strated by annexin V/propidium iodide double staining
(Figure 2A) and the cleavage of caspase-9, caspase-8, cas-
pase-3, and PARP (Figure 2B) (Online Supplementary
Appendix). Finally, we translated our experiments from
the in vitro assays described above to the in vivo setting of
a mouse model. The antitumor activity of QTX125 was
evaluated using REC-1 cells xenografted in nude mice
(Online Supplementary Appendix). We randomly selected 8
mice as the control group treated with vehicle and anoth-
er 8 for QTX125 treatments (intraperitoneal administra-
tion of 60 mg/kg in two different regimens). Tumor vol-
ume was monitored every two days. The use of the
HDAC6 inhibitor QTX125 was significantly associated
with the inhibition of lymphoma growth in comparison
to the control group (Figure 2C). The extent of blockage
of tumor growth was similar to that observed in
xenografted lymphomas treated with cyclophosphamide,
a DNA alkylating drug commonly used in MCL thera-
py.11,12 Use of QTX125 was also associated with the
growth inhibition of a second xenografted MCL cell line,
MINO (Figure 2C). The cytotoxicity of QTX125 was also
evaluated in 2 primary samples obtained from patients
with MCL (see Online Supplementary Table S1 for details
of patients’ samples). Incubation with QTX125 strongly
reduced cell viability, with IC50 values of 0.120 and
0.182 μM. (Figure 3A). Non-malignant lymphocytes,
such as peripheral blood mononuclear cells (PBMCs),
CD3+ cells (T cells) and CD19+ (B cells) were more resist-
ant to QTX125–mediated growth inhibition (Figure 3B)
than MCL cell lines (Online Supplementary Figure S1) or
MCL primary samples (Figure 3A). 
Overall, our results show that the QTX125 compound
obtained is a new HDAC6-specific inhibitor that inhibits
cell-growth inhibition and causes programmed cell death
in association with increased levels of acetylated α-tubu-
lin, its most recognizable target. The antitumoral effect is
particularly evident in MCL models, both in culture and
in vivo, surpassing the efficacy of currently available
HDAC6 inhibitors. We demonstrate, therefore, the effi-
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Figure 3. QTX125 use in primary mantle cell lymphoma (MCL) samples and normal blood. (A) Effect of QTX125 in cell viability determined by flow cytometry of
AnnexinV/7AAD negative cells in primary MCL samples from the patients AA3319 and AA9683. IC50 values are shown for each sample. (B) Effect of QTX125 in
cell viability determined by flow cytometry of AnnexinV/7AAD negative cells in peripheral blood mononuclear cells (PBMCs), CD3+ and CD19+ cells obtained from
healthy donors (n=4). IC50 values are shown for each sample.
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cacy of QTX125 in the pre-clinical setting and suggest it
warrants further assessment as a novel candidate agent
for use  in epigenetic lymphoma therapy. 
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